Sugi Predict

Sugi Predict / Compounds / SCHEMBL3769795

SCHEMBL3769795

SCHEMBL3769795

Cc1cccc2nc(Nc3ccc4c(=O)[nH][nH]c4c3)nc(Nc3cc(C4CC4)n[nH]3)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.35
▸ GRK6 P43250 3/20 0.35
▸ ULK1 O75385 4/20 0.35
▸ PDK1 Q15118 1/20 0.35
▸ ULK2 Q8IYT8 1/20 0.35
▸ SYK P43405 2/20 0.34
▸ DAPK3 O43293 1/20 0.34
▸ JAK2 O60674 1/20 0.34
▸ STK16 O75716 1/20 0.34
▸ MAP4K4 O95819 1/20 0.34
▸ PAK4 O96013 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ LCK P06239 1/20 0.34
▸ FYN P06241 1/20 0.34
▸ RET P07949 1/20 0.34
▸ LTK P29376 1/20 0.34
▸ TTK P33981 1/20 0.34
▸ GRK5 P34947 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3761449 0.88 AURKA (0.38) AURKAGRK6VRK1IGF1RSRC
SCHEMBL3767353 0.87 ULK1 (0.47) AURKAULK1PDK1ULK2SRC
SCHEMBL13054446 0.85 ULK1 (0.52) ULK1PDK1ULK2PAK4IGF1R
SCHEMBL3762117 0.84 SYK (0.35) ULK1PDK1ULK2SYKDAPK3
SCHEMBL3767787 0.84 ULK1 (0.49) AURKAULK1PDK1ULK2SRC
SCHEMBL3757377 0.84 ULK1 (0.51) AURKAULK1PDK1ULK2SRC
SCHEMBL3767239 0.83 NTRK1 (0.40) ULK1PDK1ULK2PAK4IGF1R
SCHEMBL3767838 0.82 VRK1 (0.39) SYKDAPK3JAK2STK16MAP4K4
SCHEMBL3769388 0.82 NTRK1 (0.40) ULK1PDK1ULK2PAK4
SCHEMBL3767946 0.82 ULK1 (0.40) ULK1PDK1ULK2PAK4GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842712-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 — — US disclosed
US-7842712-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 — — US disclosed
US-7842712-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 — — US disclosed
US-20090048250-A1 INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-02-19 — — US disclosed
US-20090048250-A1 INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-02-19 — — US disclosed
US-20090048250-A1 INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-02-19 — — US disclosed
US-7262200-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-28 — — US disclosed
US-7262200-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-28 — — US disclosed
US-7262200-B2 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-28 — — US disclosed
US-20040167121-A1 Indazolinone compositions useful as kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2004-08-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167121-A1 Indazolinone compositions useful as kinase inhibitors LCK, CDK2, CILK1 AURKA 7/4885GRK6 562/4885ULK1 575/4885
US-20090048250-A1 INDAZOLINONE COMPOSITIONS USEFUL AS KINASE INHIBITORS LCK, CDK2, MKNK2 AURKA 10/4885GRK6 536/4885ULK1 585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.